To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
11 Current news from luxembourg
rss
New research method provides better insights into the world of microbes
01-08-2012
A team of Luxembourg-based researchers, working at the Luxembourg Centre for Systems Biomedicine, has developed a research method that will allow scientists to study microbes in more depth than ever before. Microbes, such as bacteria, fungi and viruses, are invisible to the human eye but have ...
Creabilis appoints Dr Simon Russell as Chief Business Officer
07-05-2012
Creabilis SA announces that Dr Simon Russell has been appointed as Chief Business Officer. Dr Russell joins Creabilis from Novartis Pharma AG where he held a number global strategic marketing roles and most recently Head of Global Marketing for ILARIS (canakinumab). He was previously Head of ...
Creabilis Raises €15M in Series B Fundraising Round
05-10-2011
Creabilis SA has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company’s ...
Creabilis Expands Senior Management Team
22-08-2011
Creabilis SA announced the expansion of its senior management team with the appointment of three experienced international pharmaexecutives. Alex Leech joins as Vice President, Head of Finance and Operations, James Sandy as Senior Vice President, Head of Development, and Peter Spargo as ...
Creabilis appoints Dr David Roblin as Chief Medical Officer
08-08-2011
Creabilis SA announced that Dr David Roblin has been appointed Chief Medical Officer.Dr Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years and which has seen him deliver several drugs to the market. He has held leadership roles in ...
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris
14-03-2011
Creabilis SA announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris. CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis’ LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities with ideal ...
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Atopic Dermatitis
22-12-2010
Creabilis SA announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis. CT327 is a novel topically applied TrkA kinase inhibitor developed using the Creabilis’ LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities with ...
Creabilis Appoints Dr. Eliot Forster as its New Chief Executive Officer
04-10-2010
Creabilis SA announced the appointment of Eliot Forster as its new Chief Executive Officer. Dr Forster brings to Creabilis significant drug development experience having brought a number of molecules to market. Dr Forster has close to 20 years industry experience in biotechnology and ...
Creabilis Appoints George F. Horner III as its Chairman
16-09-2010
Creabilis SA announced the appointment of George F. Horner III as its Chairman. Mr Horner brings to Creabilis an unrivalled track record in building successful biotech businesses that have generated significant value for their shareholders. Mr Horner has over 40 years industry experience ...
Basilea's Toctino receives marketing authorization in Belgium and Luxemburg
12-03-2009
Basilea Pharmaceutica Ltd. announced that Toctino® (alitretinoin), a once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the health authorities in Belgium (Agence Fédérale des Medicaments et des ...
Netmeeting
